CL2019002919A1 - Vmat2 inhibitory compounds and related compositions. - Google Patents

Vmat2 inhibitory compounds and related compositions.

Info

Publication number
CL2019002919A1
CL2019002919A1 CL2019002919A CL2019002919A CL2019002919A1 CL 2019002919 A1 CL2019002919 A1 CL 2019002919A1 CL 2019002919 A CL2019002919 A CL 2019002919A CL 2019002919 A CL2019002919 A CL 2019002919A CL 2019002919 A1 CL2019002919 A1 CL 2019002919A1
Authority
CL
Chile
Prior art keywords
compounds
inhibitory compounds
related compositions
vmat2
pharmaceutically acceptable
Prior art date
Application number
CL2019002919A
Other languages
Spanish (es)
Inventor
Nicole Harriot
Donald Hettinger
Shawn Branum
Jeffrey C Culhane
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019002919(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CL2019002919A1 publication Critical patent/CL2019002919A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

SE PROPORCIONA UN COMPUESTO SELECCIONADO DE COMPUESTOS DE FÓRMULA (I) Y SALES, SOLVATOS E HIDRATOS FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE R1 , R2 , R3 Y R4 SON TAL COMO SE DEFINEN EN EL PRESENTE DOCUMENTO. TALES COMPUESTOS SON INHIBIDORES DEL TRANSPORTADOR VESICULAR DE MONOAMINAS 2 (VMAT2) Y TIENEN UTILIDAD PARA TRATAR, POR EJEMPLO, ENFERMEDADES Y TRASTORNOS NEUROLÓGICOS Y PSIQUIÁTRICOS. TAMBIÉN SE DAN A CONOCER COMPOSICIONES QUE CONTIENEN TALES COMPUESTOS EN COMBINACIÓN CON UN PORTADOR FARMACÉUTICAMENTE ACEPTABLE, ASÍ COMO MÉTODOS RELATIVOS A SU USO EN SUJETOS QUE LO NECESITAN.A SELECTED COMPOUND OF FORMULA (I) COMPOUNDS AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES AND HYDRATES ARE PROVIDED THEREOF, IN WHICH R1, R2, R3 AND R4 ARE AS DEFINED IN THIS DOCUMENT. SUCH COMPOUNDS ARE INHIBITORS OF MONOAMINE VESICULAR TRANSPORTER 2 (VMAT2) AND ARE USEFUL TO TREAT, FOR EXAMPLE, NEUROLOGICAL AND PSYCHIATRIC DISEASES AND DISORDERS. COMPOSITIONS CONTAINING SUCH COMPOUNDS IN COMBINATION WITH A PHARMACEUTICALLY ACCEPTABLE CARRIER ARE ALSO DISCLOSED, AS WELL AS METHODS RELATING TO THEIR USE IN SUBJECTS IN NEED OF IT.

CL2019002919A 2017-04-19 2019-10-14 Vmat2 inhibitory compounds and related compositions. CL2019002919A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487413P 2017-04-19 2017-04-19
US201862652837P 2018-04-04 2018-04-04

Publications (1)

Publication Number Publication Date
CL2019002919A1 true CL2019002919A1 (en) 2020-01-17

Family

ID=62111264

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002919A CL2019002919A1 (en) 2017-04-19 2019-10-14 Vmat2 inhibitory compounds and related compositions.

Country Status (16)

Country Link
US (1) US11040970B2 (en)
EP (1) EP3612532B1 (en)
JP (1) JP7170662B2 (en)
KR (1) KR20190140968A (en)
CN (1) CN110770236B (en)
AU (1) AU2018254429A1 (en)
BR (1) BR112019021853A2 (en)
CA (1) CA3060251A1 (en)
CL (1) CL2019002919A1 (en)
CO (1) CO2019011604A2 (en)
JO (1) JOP20190239A1 (en)
MA (1) MA50145A (en)
MX (1) MX2019012336A (en)
PE (1) PE20191784A1 (en)
TW (1) TW201841913A (en)
WO (1) WO2018195121A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051829A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
JP7250006B2 (en) 2017-09-21 2023-03-31 ニューロクライン バイオサイエンシーズ，インコーポレイテッド High-Dose Valbenazine Formulations and Related Compositions, Methods and Kits
KR20200066661A (en) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 Methods of administering certain VMAT2 inhibitors
EP3806856A1 (en) * 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
BR112021000019A2 (en) 2018-08-15 2021-04-06 Neurocrine Biosciences Inc. METHODS FOR ADMINISTERING CERTAIN VMAT2 INHIBITORS
WO2020086765A1 (en) * 2018-10-24 2020-04-30 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
CR20230448A (en) 2021-03-22 2023-10-27 Neurocrine Biosciences Inc Vmat2 inhibitors and methods of use
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
WO2023023593A1 (en) 2021-08-20 2023-02-23 Neurocrine Biosciences, Inc. Methods of screening for vmat2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
KR100744893B1 (en) 2003-06-20 2007-08-01 에프. 호프만-라 로슈 아게 Hexahydropyridoisoqinolines as dpp-iv inhibitors
EP1776160A1 (en) 2004-08-13 2007-04-25 Omeros Corporation Novel serotonin receptor ligands and their uses thereof
US8039627B2 (en) * 2006-11-08 2011-10-18 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
FR2912145B1 (en) 2007-02-02 2009-03-06 Servier Lab NOVEL TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2009126305A1 (en) 2008-04-11 2009-10-15 The Trustees Of Columbia University Glucose metabolism modulating compounds
AU2009303758B8 (en) 2008-09-18 2015-02-19 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US8772301B2 (en) 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102285984B (en) 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 Preparation method of (2R, 3R, 11bR)-dihydrotetrabenazine and relevant compounds
WO2014043866A1 (en) 2012-09-19 2014-03-27 中国科学院福建物质结构研究所 Thiophene [2, 3-d] pyrimidine derivative, and preparation method and use thereof
AU2015213778B2 (en) 2014-02-07 2020-04-23 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
EP3253752B1 (en) * 2015-02-06 2023-08-16 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
ES2934230T3 (en) 2016-12-22 2023-02-20 Incyte Corp Benzooxazole derivatives as immunomodulators
HRP20221216T1 (en) 2016-12-22 2022-12-23 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor

Also Published As

Publication number Publication date
JP2020517607A (en) 2020-06-18
CO2019011604A2 (en) 2019-10-31
MA50145A (en) 2020-07-29
WO2018195121A1 (en) 2018-10-25
EP3612532A1 (en) 2020-02-26
EP3612532C0 (en) 2023-12-13
BR112019021853A2 (en) 2020-05-26
MX2019012336A (en) 2020-07-14
US11040970B2 (en) 2021-06-22
JP7170662B2 (en) 2022-11-14
US20200131173A1 (en) 2020-04-30
TW201841913A (en) 2018-12-01
AU2018254429A1 (en) 2019-11-07
CA3060251A1 (en) 2018-10-25
CN110770236A (en) 2020-02-07
EP3612532B1 (en) 2023-12-13
CN110770236B (en) 2023-03-24
JOP20190239A1 (en) 2019-10-09
KR20190140968A (en) 2019-12-20
PE20191784A1 (en) 2019-12-24

Similar Documents

Publication Publication Date Title
CL2019002919A1 (en) Vmat2 inhibitory compounds and related compositions.
CL2019002777A1 (en) Compounds that inhibit the mcl-1 protein.
CL2019000368A1 (en) CDK2 / 4/6 inhibitors.
CO2017002998A2 (en) Tetrahydronaphthalene derivatives that inhibit mcl-1 protein
CL2020001546A1 (en) 4-azaindole compounds.
SV2016005328A (en) NEW DERIVATIVES OF PIRAZOLO PIRIMIDINA AND ITS USE AS INHIBITORS OF MALT1
PH12015501934A1 (en) New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors
PE20190395A1 (en) PYRIMIDIN-2-ILAMINO-1H-PYRAZOLES AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS
CL2014003181A1 (en) Compounds derived from n-substituted benzamides or n-substituted pyridinamides; pharmaceutical composition that includes them; treatment method; and its use for the treatment of selected diseases or disorders of pain, depression and cardiovascular, respiratory or psychiatric diseases or combinations thereof.
UY35617A (en) 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS
AR093244A1 (en) SUBSTITUTED BENZENE COMPOUNDS USED IN THE TREATMENT OF EZH2-DISORDERS
CL2019001495A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors.
UY32180A (en) VANILLOID POTENTIAL TRANSITORY RECEIVER ANTAGONISTS 1 (TRPV1)
GT201600091A (en) DERIVATIVES OF PURINA 2, 6-SUBSTITUTES AND ITS USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS
ECSP109958A (en) PIRIMIDINE DERIVATIVES 934
AR104731A1 (en) BENZAMIDS REPLACED AND METHODS TO USE THEM
PE20190964A1 (en) DOPAMINE-B-HYDROXYLASE PENETRANT INHIBITORS OF THE HEMATOENCEPHALIC BARRIER
ECSP21011232A (en) NEW HETEROCYCLIC AMINE DERIVATIVE AND COMPOSITION OF THE PHARMACEUTICAL COMPOSITION
CU24550B1 (en) AZA-INDAZOLE COMPOUNDS USEFUL IN INJURIES OF TENDONS AND / OR LIGAMENTS
DOP2015000214A (en) NEW INHIBITING COMPOUNDS OF TYPE 10A PHOSPHODIESTERASE
CO2020016080A2 (en) Compounds
UY37348A (en) ANTIBACTERIAL AGENTS OF 2-PIRROLIDIN PHENYL HYDRAZIDS
AR099071A1 (en) NR2B SELECTIVE ANTAGONISTS
CO2018007436A2 (en) Alkyl dihydroquinolinsulfonamide compounds
CU24553B1 (en) INDAZOLE COMPOUNDS USEFUL IN INJURIES OF TENDONS AND / OR LIGAMENTS